These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 2604892)

  • 21. Efficacy of once-daily extended-release lovastatin as compared to immediate-release lovastatin in patients with hypercholesterolemia.
    Lukacsko P; Walters EJ; Cullen EI; Niecestro R; Friedhoff LT
    Curr Med Res Opin; 2004 Jan; 20(1):13-8. PubMed ID: 14741066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effect of celiprolol and metoprolol on serum lipids in patients with various forms of hyperlipoproteinemia].
    Pristautz H; Stradner F
    Wien Med Wochenschr; 1986 Sep; 136(17):443-8. PubMed ID: 2879389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in the concentration and composition of lipids and lipoproteins in primary hyperlipoproteinemia during treatment with bezafibrate.
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Arzneimittelforschung; 1983; 33(8):1185-90. PubMed ID: 6685498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effect of combined treatment with lovastatin and colestipol on serum lipids and lipoproteins].
    Kłosiewicz-Latoszek L; Nowicka G; Szostak WB
    Wiad Lek; 1993 Aug; 46(15-16):581-5. PubMed ID: 7975581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The effect of fenofibrate in various types of hyperlipoproteinemias].
    Sucić M
    Lijec Vjesn; 1989 Mar; 111(3):93-7. PubMed ID: 2747411
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effects of simvastatin on plasma levels of lipids, lipoproteins and apolipoproteins in primary hypercholesterolemia].
    Caruzzo C; Uslenghi E; Varbella F; Caruzzo E; Marcolongo M; Brusca A
    Minerva Cardioangiol; 1989 Dec; 37(12):509-15. PubMed ID: 2695857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipid altering or antioxidant vitamins for patients with coronary disease and very low HDL cholesterol? The HDL-Atherosclerosis Treatment Study Design.
    Brown BG; Zhao XQ; Chait A; Frohlich J; Cheung M; Heise N; Dowdy A; DeAngelis D; Fisher LD; Albers J
    Can J Cardiol; 1998 Apr; 14 Suppl A():6A-13A. PubMed ID: 9594927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Bezalip in the treatment of hyperlipoproteinemia].
    Ceska R; Sobra J; Procházková P; Kvasilová M
    Cas Lek Cesk; 1990 Jan; 129(1):20-2. PubMed ID: 2331712
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia.
    Vacek JL; Dittmeier G; Chiarelli T; White J; Bell HH
    Am J Cardiol; 1995 Jul; 76(3):182-4. PubMed ID: 7611158
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of Artichoke dry extract in patients with hyperlipoproteinemia.
    Englisch W; Beckers C; Unkauf M; Ruepp M; Zinserling V
    Arzneimittelforschung; 2000 Mar; 50(3):260-5. PubMed ID: 10758778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).
    Blankenhorn DH; Azen SP; Kramsch DM; Mack WJ; Cashin-Hemphill L; Hodis HN; DeBoer LW; Mahrer PR; Masteller MJ; Vailas LI; Alaupovic P; Hirsch LJ;
    Ann Intern Med; 1993 Nov; 119(10):969-76. PubMed ID: 8214993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The clinical instrumental evaluation of treatment efficacy in patients with concomitant atherosclerosis of the coronary, cerebral and peripheral arteries].
    Karpov RS; Dudko VA; Shipulin VM; Kanskaia NV; Koshel'skaia OA; Stepanian NA; Fedorova NA; Balabanova AV
    Ter Arkh; 1991; 63(4):90-3. PubMed ID: 2068687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nicotinic acid for the treatment of hyperlipoproteinemia.
    Drood JM; Zimetbaum PJ; Frishman WH
    J Clin Pharmacol; 1991 Jul; 31(7):641-50. PubMed ID: 1894760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term experience with lovastatin treatment in patients with coronary heart disease and hyperlipoproteinaemia type II.
    Zhukova I; Yurenev A; Kukharchuk V; Pomerantsev E; Titov V; Shabalkin B; Martinov A
    Eur Heart J; 1992 Jul; 13 Suppl B():7-10. PubMed ID: 1644101
    [No Abstract]   [Full Text] [Related]  

  • 35. [Blood thyroid hormones in ischemic heart disease (a comparison with coronary angiographic data, severity of stenocardia and blood lipid level)].
    Sidorenko BA; Begliarov MI; Titov VN; Masenko VP; Parkhimovich RM
    Kardiologiia; 1981 Dec; 21(12):96-101. PubMed ID: 7329025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lovastatin alters blood rheology in primary hyperlipoproteinemia: dependence on lipoprotein(a)?
    Koenig W; Hehr R; Ditschuneit HH; Kuhn K; Ernst E; Rosenthal J; Hombach V
    J Clin Pharmacol; 1992 Jun; 32(6):539-45. PubMed ID: 1634641
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Evaluation of the effectiveness of hypolipidemic preparations in coronary arteriosclerosis].
    Bobkova VI; Lokshina LI; Sidakova MM; Tananova GV; Fomchenkov SI
    Kardiologiia; 1984 Sep; 24(9):54-7. PubMed ID: 6521249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic effect of gevilon in patients with hyperlipoproteinaemia.
    Milewicz A; Plamieniak Z; Bohdanowicz-Pawlak A
    Mater Med Pol; 1992; 24(2):91-5. PubMed ID: 1307777
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Plasma lipoprotein levels and functional status of thrombocytes in patients with ischemic heart disease during treatment with essential phospholipids].
    Belousova SS; Bogoslovskaia SI; Silagina LM
    Kardiologiia; 1985 Sep; 25(9):112-5. PubMed ID: 4079219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Diagnostic strategies for evaluating lipid metabolism disorders and therapeutic goals].
    Cremer P; Nagel D
    Internist (Berl); 1992 Jan; 33(1):32-7. PubMed ID: 1551761
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.